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Abstract
Introduction Major blood loss can often be life-threatening and
is most commonly encountered in the settings of surgery and
trauma. Patients receiving anticoagulant therapy are also at
increased risk of bleeding. We investigated the use of a
prothrombin complex concentrate (PCC; Beriplex P/N, CSL
Behring, Marburg, Germany) to treat severe bleeding in a variety
of settings: cardiac surgery, warfarin therapy and other surgery.
Methods Thirty consecutive patients who had received PCC
were identified from blood transfusion records. For cardiac
surgery and warfarin reversal, PCC was administered in
accordance with hospital protocols. PCC was administered to
cardiac and other surgical patients responding poorly to
recognized blood products, whereas it was administered first-
line to patients with life-threatening bleeds and requiring
warfarin reversal, in accordance with British Committee for
Standards in Haematology guidelines. We conducted a
retrospective analysis of patient records in order to ascertain
PCC dose, use of other blood products and response to PCC
(clotting screen results before and after PCC administration,
haemostasis achievement, and survival).
Results Six patients (20%) were excluded because of
inadequate documentation (n = 5) or acquired haemophilia (n =
1). Therefore, 24 patients were included in the analysis:
coronary artery bypass graft (n = 5), mitral/aortic valve
replacement (n = 2), other surgery (n = 9) and warfarin reversal
(n = 8). Most patients (83.3%) received no more than 1500 IU
of Beriplex P/N 500. Considerable reduction in administration of
other blood products was seen during the 24 hours after PCC
administration. Partial or complete haemostasis was achieved in
14 out of 18 cases (77.8%). In total, 12 out of 24 patients (50%)
died during the study; two-thirds of the deaths were considered
unrelated to bleeding. No thrombotic complications or adverse
drug reactions were observed.
Conclusion This study emphasizes the value of PCC in
reversing the effects of oral anticoagulant therapy in bleeding
patients. It also demonstrates the potential value of PCC in
controlling bleeding in patients undergoing cardiac and other
surgical procedures. The use of PCC in bleeding patients
without hereditary or anticoagulation-related coagulopathy is
novel, and further investigation is warranted. In the future, it may
be possible to use PCC as a substitute for fresh frozen plasma
in this setting; adequate documentation is crucial for all blood
products.
Introduction
Major blood loss, defined as loss of 20% or more of total blood
volume [1], is a significant clinical challenge and can often be
life-threatening. It is most commonly encountered in surgical
and trauma patients. Patients receiving anticoagulant therapy
are also at increased risk of bleeding. Major bleeding contrib-
utes to approximately 30% of trauma-related deaths [1,2],
starkly illustrating the need to optimize the management of
affected patients.
Following immediate measures to control bleeding, the broad
principles for managing massive blood loss have been summa-
rized as follows: restore volume (administer colloids or crystal-
loids), perform laboratory investigations (full blood count,
blood group and cross-match, coagulation screening and bio-
chemistry), administer blood component therapy (red blood
cells, platelets, fresh frozen plasma [FFP] or cryoprecipitate),
and administer appropriate pharmacological agents (for
instance, antifibrinolytic drugs or recombinant activated factor
ACR: anticoagulant reversal; APTT: activated partial thromboplastin time; CABG: coronary artery bypass graft; FFP: fresh frozen plasma; INR: inter-
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VII) [3]. There is therefore a variety of therapeutic options for
achieving haemostasis, depending on the clinical situation.
Anticoagulant-related bleeding differs slightly in that the cause
is readily identifiable as deficiency in vitamin K dependent
coagulation factors. Major bleeding among patients receiving
oral anticoagulant therapy (OAT) is common, affecting some
6.5% of patients per year [4]. It is often serious, with a fatality
rate of approximately 1% across all age ranges, mainly due to
intracerebral haemorrhage [4]. Present-day prothrombin com-
plex concentrates (PCCs) provide a source of the four vitamin
K dependent coagulation factors, and consequently these
agents are recommended in both Europe and the USA for
emergency anticoagulant reversal (ACR) [5-8]. Bleeding in
haemophilia patients with inhibitors (for example, antibodies
against factors VIII or IX) may also be treated with activated
PCC [9]. Although PCC is an established therapy in these set-
tings, little investigation of their use in bleeding related to sur-
gery has been conducted. This could be related to historical
safety concerns with PCCs [10,11], but there is considerable
evidence demonstrating that thrombogenic risk has been min-
imized with current PCCs, especially in patients without under-
lying risk factors for thrombosis [12-16].
In 2001, a report of two cardiac surgery cases in which bleed-
ing was controlled using a PCC demonstrated the potential
application of PCC in this setting [17]. We were therefore
keen to investigate the use of PCC to manage severe bleeding
in this patient group. We were also keen to include all patients
receiving PCC within our institute, partly for comparative rea-
sons but also to provide evidence for the effectiveness of PCC
in a broad patient setting. Treatment protocols were devel-
oped by consultant haematologists, for use of PCC in the set-
tings of ACR and cardiac surgery, and we conducted a
retrospective analysis of outcomes in 30 consecutive patients
treated with PCC. Given this variety of cases, outcomes were
considered separately for each patient group.
Materials and methods
At Derriford Hospital in Plymouth, UK, 30 consecutive patients
were identified from blood transfusion records as having
received PCC (Beriplex P/N 500, CSL Behring, Marburg, Ger-
many) over a 27-month period between April 2002 and July
2004. Each PCC vial provided factor II (400 to 960 IU), factor
VII (200 to 500 IU), factor IX (400 to 620 IU) and factor X (440
to 1,200 IU), as well as the coagulation inhibitors protein C
(300 to 900 IU), protein S (260 to 520 IU), antithrombin (4 to
30 IU) and heparin (8 to 40 IU). The total protein content was
6 to 14 mg/ml reconstituted solution.
For cardiac surgery, PCC was used according to a predefined
hospital protocol in patients responding poorly to recognized
blood products (FFP, platelets and cryoprecipitate). These
more traditional blood products were administered as follows,
in accordance with hospital guidelines, which were based on
British Committee for Standards in Haematology guidelines
[18,19]. FFP (dose 15 to 20 ml/kg) was administered when
clotting was deranged and the patient was bleeding. Platelets
(one adult therapeutic dose) were given when the patient's
level dropped below 50 × 109/l and the patient was bleeding.
Cryoprecipitate (one dose equivalent to 10 packs) was admin-
istered when the fibrinogen level dropped below 1.0 g/l and
the patient was bleeding. Clinical judgement was also involved
in the decision-making process. Poor response, for triggering
PCC administration, was defined as continued bleeding in
spite of near correction of clotting parameters (activated par-
tial thromboplastin time [APTT], prothrombin time [PT], fibrin-
ogen level and thromboelastography; Table 1). A similar
approach was adopted in patients undergoing other types of
surgery (hence their receipt of PCC). In patients requiring
ACR, PCC was used as first-line therapy in all patients with
major bleeding, provided the thrombotic risk did not outweigh
the risk of continued bleeding, in accordance with British
Committee for Standards in Haematology guidelines [20].
Table 1 shows the treatment protocol implemented by the hos-
pital for the majority of these patients. The treatment protocols,
including doses, were devised from review of the literature and
from the package inserts, for warfarin reversal. The time of dos-
ing depended on clinical circumstances, as soon as major
bleed suspected for warfarin reversal and upon clinical evi-
dence of ongoing bleeding for surgical patients, together with
relatively normal clotting or that which could not be corrected
with traditional clotting components. In all cases, PCC was
administered intravenously at a rate of approximately 15 to 20
minutes per vial.
The following details were noted for each patient: age, under-
lying medical condition, dose of PCC administered (quantified
in IU factor IX, assuming that each vial contains 500 IU), use
of other blood products (blood, FFP, cryoprecipitate and plate-
lets), clotting screen results (before and after administration of
PCC) and clinical outcomes (haemostasis and survival). Blood
samples were taken before and after PCC administration for
clotting screen tests (PT and APTT) and for measurement of
fibrinogen levels. Although international normalized ratio (INR)
is the established investigation for patients requiring control of
OAT, this was frequently not recorded in this patient group.
Therefore, the PT, APTT and fibrinogen results are provided
wherever tested, and this provides standardization across all
of the patient groups.
Results
Of the initial 30 patients, a total of 24 were included in the
analysis. Five patients were excluded because of lack of doc-
umentation of timing or administration of PCC, and one further
patient with acquired haemophilia was withdrawn. The mean
age of patients included in the analysis was 68.5 years (range
41 to 82 years).Available online http://ccforum.com/content/12/4/R105
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Four distinct patient groups were identified: coronary artery
bypass graft (CABG; n = 5), mitral/aortic valve replacement (n
= 2), other surgery (n = 9) and warfarin reversal (n = 8). 'Other
surgery' included an abdominal aortic aneurysm rupture repair,
an infected aortic graft repair, a thoracic aorta repair after aor-
tic valve replacement, repair of an aortic dissection, splenec-
tomy, debulking of a gynaecological cancer and debridement
of necrotizing fasciitis. Two further patients placed in this cat-
egory underwent multiple procedures: one CABG and
nephrectomy; and one CABG, valve replacement and abdom-
inal aortic aneurysm repair. One of the warfarin reversal
patients needed emergency surgery for bowel obstruction,
and the other seven had intracranial bleeding.
The dose of PCC administered is shown in Table 2, together
with the subsequent changes in blood product administration.
Table 1
The Derriford protocols for using PCC in patients with severe bleeding associated with warfarin and cardiac reversal
Indication Details
Cardiac surgery There have been some limited data from a few sources regarding the benefit of using Beriplex (a PCC) within the 
context of life-threatening bleeding associated with cardiothoracic surgery. Much of these data in the UK are provided 
by the Cardiothoracic Unit of Southampton General Hospital. Investigators there have used Beriplex in more than 100 
patients, both paediatric and adult, with very good effect, particularly when there are volume concerns and in the 
paediatric population.
They have experienced no episodes of thrombosis when using one to two vials Beriplex P/N 500 only. 2.
1. Beriplex should only to be given after administration of sufficient recognized blood products (FFP, platelets or 
cryoprecipitate) but with limited effect on bleeding in spite of documented continued coagulopathy based on 
laboratory data
2. This should usually occur within the context of TEG data being unable to demonstrate clear abnormalities
3. The maximum Beriplex usage should be two vials of P/N 500. The suggestion is to give a single vial initially, 
followed by a second vial if bleeding is obviously continuing. This respects the prothrombotic nature of Beriplex
4. There should be adequate fibrinogen to produce a reasonable clot. Therefore, fibrinogen levels should be 
monitored and kept above 1.0 g/l if possible
5. Note that Beriplex is held in blood transfusion and should only be administered after consultation with consultant 
haematologist
Anticoagulant (warfarin) 
reversal
In patients with life-threatening bleeding on warfarin (or other oral vitamin K antagonists), rapid reversal of 
anticoagulation is indicated if the thrombotic risks of complete reversal are relatively less than the risk of continuing 
bleeding. If the bleeding risk is greater, then Beriplex may be used for reversal on the understanding that this product 
is itself prothrombotic. This policy is endorsed by guidelines on oral anticoagulation [20]. Beriplex P/N 250 contains 
clotting factors II (200 to 480 IU), VII (100 to 250 IU), IX (200 to 310 IU) and X (220 to 600 IU), as well as protein C 
(150 to 450 IU) and protein S (130 to 260 IU)[13,32]. Beriplex P/N 500 contains approximately double these values 
of vitamin K dependent clotting factors. The 250/500 values relate to the factor IX content. In the majority of patients, 
FFP is not recommended because it does not completely reverse the anticoagulation effect of warfarin when it is 
given in quantities according to guidelines; calculated volumes would be clinically excessive [12]. FFP also requires 
slow thawing, which will delay reversal.
The majority of fatal, anticoagulant-related bleeds are intracranial, in which the volume of bleeds is double [33], tend to 
enlarge more rapidly [34] and are associated with twice the mortality compared with intracranial bleeds in those not 
taking anticoagulants [33]. In order to maintain reversal, intravenous vitamin K is indicated, producing 70% correction 
of INR at 8 hours [33]. This dual approach is safe, with rapid replacement of clotting factors and few documented 
thromboses[12,13]. If possible, a repeat coagulation screen should be performed before surgery, and further doses of 
Beriplex should be avoided, respecting its thrombotic potential.
There may be concerns related to the continuing anticoagulation of patients (particularly those with heart valves) after 
control of the bleeding episode. Advice should be sought from haematologists or cardiologists.
Guideline for correction of Warfarin-associated life-threatening bleeding:
Immediate:
1. Beriplex P/N. Dose (INR): 25 IU/kg (2.0 to 3.9), 35 IU/kg (4.0 to 6.0) and 50 IU/kg (>6.0). For instance, eight vials 
of Beriplex P/N 500 for an 80 kg patient with INR >6.0. Beriplex to be given by slow intravenous injection over 10 to 
15 minutes
2. Vitamin K intravenous 2 to 5 mg
Later:
Consider repeating vitamin K administration 24 hours later, in those patients previously severely over-
anticoagulated. An INR will help guide this decision together with clinical assessment
FFP, fresh frozen plasma; INR, International Normalized Ratio; PCC, prothrombin complex concentrate; TEG, thromboelastography.Critical Care    Vol 12 No 4    Bruce and Nokes 
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Most patients (83.3%) received no more than 1,500 IU of
PCC. Higher doses of PCC were administered to patients
undergoing CABG or requiring ACR, as compared with those
undergoing valve replacement or other surgery. In accordance
with the protocol, the original dose of PCC for cardiac surgery
was 500 to 1,000 IU only. The main reason for this restriction
was the potential for thrombosis, particularly in CABG
patients. However, patient records indicated that, after initial
PCC treatment in accordance with the protocol, increased
doses were administered if bleeding continued.
With the exception of platelets in CABG patients, considera-
ble reductions in the administration of all blood products were
observed in all of the patient groups during the 24-hour period
after PCC administration, as compared with the previous 24
hours. Figure 1 shows in greater detail the effect of PCC
administration over time on patients' requirements for FFP, red
blood cells, cryoprecipitate and platelets. In general terms, the
reduction was not immediate; rather, it accrued over the 24-
hour period after PCC administration.
For the clotting assessments, samples were taken on average
3.71 hours (range 1 to 18 hours) before PCC administration,
and 5.13 hours (range 0.5 to 19 hours) after administration of
PCC. The greatest percentage reduction in PT was observed
in the warfarin reversal group (Table 3). For APTT, the greatest
reduction was observed in the valve replacement group.
Fibrinogen levels were measured in five patients before and
after PCC administration. The mean pre-PCC level was 1.52
g/l, and this increased to 2.14 g/l after PCC administration –
a mean increase of 40.8%. None of the patients showed a
decrease in fibrinogen level after treatment with PCC.
Haemostasis outcomes were recorded in 18 patients, with
partial or complete haemostasis achieved in 14 of these
(77.8%; Table 4). Three out of the four patients not achieving
haemostasis were in the warfarin reversal group. Seven of the
14 patients who achieved haemostasis (complete in two and
partial in five) died subsequently from causes other than bleed-
ing. In total, 12 out of 24 patients (50%) died during the study
(eight [33.3%] unrelated to bleeding and four [16.6%] related
to bleeding; Table 4). Although the highest death rate was
Table 2
Units of PCC administered per patient, and resultant change in administration of blood products
Indication Mean dose per patient (IU [range]) Post-PCC changea in administration of:
FFP Red blood cells Cryoprecipitate Platelets
Cardiac surgery (CABG; n = 5) 1,500 (500–4,000) -15.8% -63.5% -50.0% 20.0%
Cardiac surgery (valve replacement; n = 2) 500 (500 to 500) -21.1% -83.3% -40.0% -66.7%
Other surgery (n = 9) 850 (500 to 2,000) -25.9% -60.3% -84.0% -29.4%
Warfarin reversal (n = 8) 1,800 (1,000 to 4,000) -50.0% N/A N/A N/A
All patients (n = 24) 1,250 (500 to 4,000) -22.7% -63.9% -70.5% -22.2%
The dose is given as IU of factor IX, assuming that each PCC vial provides 500 IU. aThe percentage change was calculated by dividing the 
quantity of blood product administered during the 24 hours after PCC administration, by the quantity administered during the 24 hours before 
PCC administration; a negative value indicates a decrease after PCC administration. CABG, coronary artery bypass graft; FFP, fresh frozen 
plasma; N/A, not available; PCC, prothrombin complex concentrate.
Figure 1
Units of blood products administered before and after PCC administration Units of blood products administered before and after PCC administration. Data shown are total numbers of units transfused for all patients (n = 23; 
data were unavailable for one patient). Cryoppt, cryoprecipitate; FFP, fresh frozen plasma; PCC, prothrombin complex concentrate.Available online http://ccforum.com/content/12/4/R105
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observed in the valve replacement group (50%), the number
of patients in this group was small and the largest number of
deaths was observed among patients undergoing 'other sur-
gery' (six fatalities among nine patients [66.7%]: four unrelated
to bleeding and two related to bleeding). The warfarin reversal
patient group exhibited both the highest rate of nonachieve-
ment of haemostasis and the highest survival rate; two of the
three patients not achieving haemostasis survived. Two-thirds
of all deaths were considered unrelated to bleeding.
No thrombotic complications or adverse drug reactions were
observed after PCC administration in any of the patients (n =
24).
Discussion
These results demonstrate successful use of PCC in patients
with severe bleeding associated with a range of circum-
stances, specifically cardiac and other types of surgery, and
need for warfarin reversal. PCC administration was followed
by a general reduction in requirement for transfusion of blood
products, and haemostasis was achieved in most patients.
The overall survival rate (50%) is favourable for such a group
of patients with life-threatening bleeding. The majority of
deaths that did occur were unrelated to bleeding.
Numerous studies have previously demonstrated the efficacy
of PCCs in OAT patients requiring rapid bleeding control
[13,15,21-26], and the data presented here lend further
support to the already established role of PCC as preferred
treatment for emergency ACR [5-8]. Coagulopathy after surgi-
cal bleeding is very different, owing to more generalized deple-
tion of coagulation factors, and there have been no major
studies of PCC in bleeding patients without pre-existing coag-
ulopathy. One previous study [14] reported successful use of
PCC in a range of critically ill patients with either active bleed-
ing or requiring imminent surgery, but all of these patients had
coagulation factor deficiencies owing to hepatic impairment.
Another article [17] reported that PCC was effective in con-
trolling bleeding in two patients undergoing cardiac surgery,
but again both patients had significant liver dysfunction. There
has also been a previous hospital-based audit of PCC (Beri-
plex P/N); all of the patients required correction of oral antico-
Table 3
Clotting screen test results: mean PT and APTT before and after administration of PCC
Clotting parameter Cardiac surgery (CABG) Cardiac surgery (valve replacement) Other surgery Warfarin reversal All patients
PT Pre-PCC 19.1 24.0 32.9 52.7 35.9
Post-PCC 15.7 13.8 15.7 14.7 15.2
Percentage change -17.8% -42.5% -52.3% -72.1% -57.7%
APTT Pre-PCC 113.4 146.1 97.3 39.4 100.8
Post-PCC 73.3 82.6 78.2 29.8 65.3
Percentage change -35.4% -43.5% -19.6% -24.4% -35.2%
APTT data were incomplete for one patient in the 'other surgery' group and for six patients in the warfarin reversal group, and so these patients 
were excluded from the analyses. APTT, activated partial thromboplastin time; CABG, coronary artery bypass graft; PCC, prothrombin complex 
concentrate; PT, prothrombin time.
Table 4
Clinical outcomes after PCC administration (haemostasis and survival)
Indication Haemostasis Survival
Complete Partial Not achieved Not recorded Death not related to 
bleeding
Death related to 
bleeding
Alive after episode
Cardiac surgery 
(CABG; n = 5)
2 (40%) 2 (40%) 0 (0%) 1 (20%) 2 (40%) 1 (20%) 2 (40%)
Cardiac surgery 
(valve replacement; n 
= 2)
0 (0%) 2 (100%) 0 (0%) 0 (0%) 1 (50%) 0 (0%) 1 (50%)
Other surgery (n = 9) 1 (11.1%) 5 (55.6%) 1 (11.1%) 2 (22.2%) 4 (44.4%) 2 (22.2%) 3 (33.3%)
Warfarin reversal (n 
= 8)
2 (25%) 0 (0%) 3 (37.5%) 3 (37.5%) 1 (12.5%) 1 (12.5%) 6 (75%)
All patients (n = 24) 5 (20.8%) 9 (37.5%) 4 (16.7%) 6 (25.0%) 8 (33.3%) 4 (16.6%) 12 (50%)
All values are presented as n (%). CABG, coronary artery bypass graft; PCC, prothrombin complex concentrate.Critical Care    Vol 12 No 4    Bruce and Nokes 
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agulation and other clotting abnormalities [27]. Again, the data
showed PCC to be safe and rapidly effective. The present
data are therefore novel in showing the potential application of
PCC in patients undergoing cardiac surgery and other surgi-
cal procedures with severe bleeding not associated with anti-
coagulation therapy, haemophilia or liver disease.
It is clear that our results should be interpreted as preliminary
findings only, and that more rigorous studies of PCC in the
specific patient groups represented in the present cohort
should be performed. The present study was retrospective
(potential risk of bias is therefore accepted), and specific data
on some aspects such as precise timings are unavailable.
There are clear needs for optimal PCC dosing to be estab-
lished and for evidence from larger patient numbers. Relative
to this study, increased consistency with study methods would
be valuable. Although all of the documented cardiac patients
were supposed to be treated in accordance with a docu-
mented protocol, this was often violated. Greater variation was
possible with warfarin patients because they were treated
before the protocol had been finalised (although the same
principles were applied). Moreover, future studies should
include a control group. A significant limitation of the present
study is that the patient outcomes cannot be attributed solely
to PCC. A variety of other blood products were administered
to the patients, and it is possible that – in some cases – these
treatments may have produced haemostasis in the absence of
PCC administration. Future studies could also include throm-
boelastography or thrombin generation assays, for maximum
insight into the effect of PCC administration [28].
There were no thrombotic adverse events in the present study,
which is important given the historical safety concerns with
PCC. The lack of such adverse events is particularly comfort-
ing in the CABG patient cohort, given the administration of
higher PCC doses than planned and the life-threatening
nature of thrombosis in these patients.
The treatment protocol that we devised for warfarin reversal is
in line with published guidelines in that setting. None of the
guidelines include specific guidance in relation to PCC dos-
ing, attributable to a lack of definitive evidence. Four studies
have examined PCC dosing: one [29] indicated that 500 IU of
PCC was likely to be optimal for correction of INR <5; another
[30] also advocated fixed dosing, showing that 500 to 1,000
IU of PCC was adequate in most patients. Two further studies
[23,31] showed that individualized dosing, based on target
INR, initial INR and body weight, is an effective approach. We
report successful use of individualized PCC dosing, based on
initial INR and body weight, and would therefore support this
approach while recognizing that further research would be
valuable.
Given the lack of experience with PCCs for surgical bleeding
not associated with underlying coagulopathy, it is important to
consider how they might fit into the overall approach to treat-
ing such patients. The possible role of PCCs might be consid-
ered analogous to that of FFP, because both products restore
levels of coagulation factors, balanced by inhibitors. We
administered PCC for surgical bleeding only after inadequate
response to platelets, cryoprecipitate and FFP. Perhaps the
next step would be investigation of PCC as a potential substi-
tute for FFP.
Conclusion
The results of this study highlight a potential role for PCC in
controlling bleeding in patients undergoing cardiac surgery
and other surgical procedures. There is a paucity of clinical
data for such broad use of PCC (including patients without
underlying coagulopathy relating to OAT, haemophilia or liver
dysfunction). Further investigation of bleeding in cardiac sur-
gery and other surgical procedures would be needed to estab-
lish the optimal use of PCC in these settings.
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